Navigation Links
Data Presented on Cempra Pharmaceutical's CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
Date:10/28/2009

CHAPEL HILL, N.C., Oct. 29 /PRNewswire/ -- Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America, 47th Annual Meeting, October 29 to November 1, 2009, in Philadelphia.

Susceptibility of CEM-101 and more than 25 other antibiotics was tested against 1,737 multidrug-resistant S. pneumoniae strains collected in 2008 from medical centers in the U.S., Europe and Latin America. CEM-101 demonstrated 100% coverage (100% inhibition at less than or equal to 1 microgram/ml) against these strains. Activity was slightly better than telithromycin (MIC90 of 0.25 microgram/ml for both; range of less than or equal to 0.008 to 1 for CEM-101 vs. less than or equal to 0.06 to 2 for telithromycin) and at least four-fold better than linezolid (MIC90 of 1 microgram/ml) or vancomycin (MIC90 of less than or equal to 1 microgram/ml). The study will be presented during a poster session on October 30.

CEM-101 is a new fluoroketolide antibiotic with potent and broad-spectrum activity against gram-positive and gram-negative pathogens, including multidrug-resistant strains, as well as non-bacterial pathogens such as Plasmodium falciparum. The compound recently completed a Phase 1 clinical trial and is in preparation for a Phase 2 trial in moderate to moderately-severe community-acquired bacterial pneumonia.

"The rise of multidrug-resistant organisms has become an increasing public health issue, particularly for vulnerable patient populations including those with challenging respiratory infections," said Prabhavathi Fernandes, Ph.D., Chief Executive Officer of Cempra Pharmaceuticals. "New medications are needed that are safe and effective against these difficult-to-treat pathogens. We believe that the growing database showing the potency and broad-spectrum activity of CEM-101, not only against the pneumococcal strains presented here, but agai
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego
2. Medical Food Reduces Medical Costs and Use of Anticonvulsant Medication When Treating Diabetic Neuropathy, According to HealthCore Study Presented at ISPOR
3. Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences
4. The Most Advanced Solution for the Reduction of Stretch Marks Based on TriPollar(R) Technology Presented at the Upcoming EADV Congress
5. Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
6. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
7. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
8. ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented
9. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
10. New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal
11. QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Ill., Dec. 16 Naurex Inc., a ... depression and other CNS disorders based on its ... data presented at a major medical meeting showed ... and anxiolytic-like activity with no signs of the ... the NMDA receptor(1). The studies also showed ...
(Date:12/16/2009)... ChemoCentryx, Inc. today announced that it ... clinical trial of CCX354, an orally-bioavailable, novel, small ... chemokine receptor for the treatment of rheumatoid arthritis ... and selective antagonist of CCR1, a chemokine receptor ... as monocytes and macrophages, associated with the inflammation ...
(Date:12/15/2009)... Wis., Dec. 16 Cellular ... commercial launch of iCell(TM) Cardiomyocytes for use in ... industry. These human heart cells are designed ... of drug compound efficacy and toxicity screens, weeding ... the pharmaceutical pipeline process before significant time and ...
Breaking Medicine Technology:Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 2ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 3ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 4ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 5Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 2Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 3Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 4Type 1 diabetes linked to immune response to wheat 54951 1Type 1 diabetes linked to immune response to wheat 54951 2Swine Flu Vaccine Delay Manageable Experts Say 54949 1Swine Flu Vaccine Delay Manageable Experts Say 54949 2Swine Flu Vaccine Delay Manageable Experts Say 54949 3MN Community Measurement Launches First Of Its Kind Quality Measure For Depression Care 54948 1MN Community Measurement Launches First Of Its Kind Quality Measure For Depression Care 54948 2MN Community Measurement Launches First Of Its Kind Quality Measure For Depression Care 54948 3
(Date:12/16/2009)... Dec. 16 Medical travel facilitator Companion ... in Puerto Rico into its network of international ... lower than those at mainland U.S. facilities. ,, ... medical travel assistance and preferred pricing for its ... treatment at either HIMA San Pablo Bayamon or ...
(Date:12/16/2009)... MassMutual,s Retirement Services Division has announced plans to ... Q2 2010. The new platform will include a ... materials in a variety of themes. Plan sponsors ... menu of creative options to support the theme ... new RetireSmart participant engagement platform will be phased ...
(Date:12/16/2009)... century shrouded man found in a tomb on the edge ... proven case of leprosy. Details of the research will be ... , The molecular investigation was undertaken by Prof. Mark Spigelman ... Center for the Study of Infectious and Tropical Diseases at ... Kim Vernon of Lakehead University, Canada, Prof. Azriel Gorski of ...
(Date:12/16/2009)... methionine, an amino acid typically found in red ... and seeds, can possibly increase the risk of ... Temple researchers. , The researchers published their findings, ... in a mouse model of Alzheimer,s disease," in ... "When methionine reaches too high a level, our ...
(Date:12/16/2009)... and Global Market Expansion , ... Ramat-Gan, Israel (PRWEB) ... Analytics to Web sites and companies, today announced a record year ... Since its launch on July 2008, Kampyle has processed more ... amassed more than 30,000 customers in 191 countries., , ,Kampyle pioneered ...
Breaking Medicine News(10 mins):Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 3Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 4Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 5Health News:DNA of Jesus-era shrouded man in Jerusalem reveals earliest case of leprosy 2Health News:DNA of Jesus-era shrouded man in Jerusalem reveals earliest case of leprosy 3Health News:Diet high in methionine could increase risk of Alzheimer's 2Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 2Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 3Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 4Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 5
... and groups across the country and around the globe are ... period. The purpose of Men,s Health Month is to ... detection and treatment of disease among men and boys. The ... the week ending on Father,s Day, a special awareness period ...
... new study is the first to show that there ... liver disease in the general U.S. adult population. This ... disease in highly-exposed chemical workers. The study is being ... ), the largest international gathering of physicians and ...
... Advance Health Care Investment OpportunitiesCHICAGO, May 29 ... private equity firm focused exclusively on the health care ... to join the firm as a partner, effective July ... Mr. Womsley, 45, will work with Water Street,s team ...
... the immune system,s response, study with mice shows , , FRIDAY, ... that drugs that affect the immune system might one day ... swine flu that,s currently circulating around the globe. , ... that were treated with the rheumatoid arthritis drug abatacept (Orencia) ...
... 29 VION PHARMACEUTICALS, INC. ... of clinical data of its lead anticancer agent Onrigin ... presented in a poster at the 2009 American Society ... poster (Abstract #7050) entitled "Comorbidity Description Using the Hematopoietic ...
... and Treatment for Patients with Shorter Recovery Time -DALLAS, ... first revolutionary AccuraScope(TM) Discectomy and Neural Decompression ... back pain in Dallas this week. North American ... procedure in the Dallas/Fort Worth area. The surgery is ...
Other Medicine News:Health News:Join Men's Health Network in Celebration of Men's Health Month 2Health News:Join Men's Health Network in Celebration of Men's Health Month 3Health News:Environmental pollution increases the risk of liver disease 2Health News:Citi Private Equity Executive Joins Water Street Healthcare Partners 2Health News:Citi Private Equity Executive Joins Water Street Healthcare Partners 3Health News:Rheumatoid Arthritis Drug Might Fight Swine Flu 2Health News:Rheumatoid Arthritis Drug Might Fight Swine Flu 3Health News:Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting 2Health News:Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting 3Health News:Kenneth L. Reed, M.D. Performs First State of the Art AccuraScope(TM) Procedure in Dallas 2
... The STA is a fully-automated, ... chromogenic and immunological assays in true ... method of sample management offers high ... samples without the need to interrupt ...
The ACL 9000 together with an extensive test menu and superior technology is backed by high-quality service to keep the lab running efficiently....
HemoSite meter can be used to measure the effects of transfusion or the treatment of deficiency states. It is fast, easy, convenient and discrete....
... The D-10 Hemoglobin Testing System delivers ... provides a fully automated system which combines ... single platform. Programs for rapid HbA1c or ... and can be easily integrated into your ...
Medicine Products: